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Background: Liver graft dysfunction can deteriorate to complete organ failure and increases perioperative
morbidity and mortality after liver transplantation. Therapeutic strategies reducing the rate of graft dysfunction are
of current clinical relevance. One approach is the systemic application of prostaglandins, which were demonstrated
to be beneficial in reducing ischemia-reperfusion injury. Preliminary data indicate a positive effect of prostacyclin
analogue iloprost on allograft viability after liver transplantation. The objective of the study is to evaluate the
impact of iloprost in a multi-center trial.
Methods/Design: A prospective, double-blinded, randomized, placebo-controlled multicenter study in a total of
365 liver transplant recipients was designed to assess the effect of intravenous iloprost after liver transplantation.
Primary endpoint will be the primary graft dysfunction characterized as presentation of one or more of the
following criteria: ALAT or ASAT level > 2000 IU/ml within the first 7 postoperative days, bilirubine ≥ 10 mg/dl on
postoperative day 7; INR ≥ 1.6 on postoperative day 7 or initial non-function. Secondary endpoints are parameters
of post-transplant morbidity, like rates of infections, biliary complications, need of clotting factors or renal
replacement therapy and the graft and patient survival.
Discussion: A well-established treatment concept to avoid graft dysfunction after liver transplantation does not
exist at the moment. If the data of this research project confirm prior findings, iloprost would improve the general
outcome after liver transplantation.
Trial Registration: German Clinical Trials Register: DRKS00003514. Current Controlled Trials Register:
ISRCTN12622749.
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The incidence of primary graft dysfunction (PDF) after LT
is approximately 25% within a range of 9.3 to 43.7% based
on different definitions characterizing PDF [1-5]. Initial
non-function (INF) develops in up to 6% of all considered
cases and requires urgent retransplantation [6].
Risk factors are prolonged cold ischemia time or higher
degree of graft steatosis and subsequent development of
severe hepatic ischemia/reperfusion injury (IRI) [5,7]. A
cascade of cellular events results in microcirculatory flow
disturbance. This may be distinguished as “no-flow” indi-
cating capillary perfusion failure on the one hand, or
“reflow-paradox” including activation of the leukocyte-
endothelium interaction, release of toxic mediators, and
impairment of the endothelial barrier on the other hand
[8,9]. There are, obviously, further different factors all con-
tributing to an insufficient function of liver grafts and its
detrimental effects on the overall outcome after LT: recipi-
ent’s condition, the donor data, the organ conservation
as well as the immunosuppression and the antibiotic re-
gime in the perioperative period. All of these factors may
influence the performance of the graft with possible
development of graft dysfunction or non-function as un-
desired outcomes.
Due to the persisting shortage of donor the transplant
centers are forced to accept so called marginal organs.
The more criteria of a marginal organ are met, the higher
is the risk for development of graft dysfunction [10].
Therapeutic strategies reducing the rate of organ dysfunc-
tion are of current clinical relevance. One approach is
the systemic application of prostaglandin derivatives. In
particular, the prostaglandins E1 (PGE1) and I2 (PGI2)
showed beneficial protective effects with respect to IRI by
improvement of tissue perfusion and by protection of
endothelial cells studied in vitro and in vivo. Both prosta-
glandins induce vasodilatation, inhibit platelet aggregation
and activation of leukocytes and exert a variety of “cyto-
protective” effects. PGI2 is believed to play a superior role
with respect to inhibition of platelet aggregation via PGE1
and also to inhibit the production of inflammatory cyto-
kines. Therefore PGE1 and PGI2 are supposed to attenuate
reperfusion injury.
There is a lack of systematic studies on the effects of
synthetic PGI2 analogue iloprost. Many authors have re-
ported the clinical use of the iloprost over the last two
decades. Based on its ability to induce vasodilatation, it
has traditionally been utilized in the treatment of pulmon-
ary hypertension [11]. Off-label use of iloprost as an adju-
vant in elective abdominal aortic aneurysm surgery and
after reconstructive surgery for acute lower limb ischemia
has been reported [12,13]. In these studies, the PGI2 in-
fusion was associated with a significant reduction of
morbidity and mortality suggesting an improved systemic
perfusion and reduced secondary end-organ damage.From 2006 to 2008, we evaluated the impact of the PGI2
analogue iloprost in 80 liver transplanted patients in a
prospective, randomized (1:1), open-label, single-center
pilot study [14]. Our data indicate that intravenous ad-
ministered PGI2 analogue iloprost (1 ng/kg BW/min)
improves the graft function, particularly in the early post-
operative period. We observed ten cases of PDF according
to the definition of Haller et al. [15]: eight in the control
group (n = 8/40, 20%), and two in the iloprost group
(n = 2/40, 5%) (relative risk 0.25, 95% confidence interval
(0.05, 1.11). The relative risk did not change after adjust-
ment to three or more extended-donor criteria (EDC).
Four out of 40 patients of the control group but none of
the iloprost group underwent liver retransplantation due
to INF (p = 0.12).
The definition of graft dysfunction after LT varies in the
literature. There is currently no standardized terminology
[7,10,15-17]. Besides, in the last years, there has been a
shift toward abandoning the routine use of T-tubes for re-
construction of the biliary tract [18]. Therefore, in a post-
hoc analysis we applied a distinct definition of PDF, which
was recently validated by Olthoff et al. [19]. This definition
utilizes objective post-transplant criteria that were highly
associated with graft loss and patient mortality. According
to Olthoff et al., we observed 27 cases of PDF (treatment
group: n = 11/40 (27.5%); control group: n = 16/40 (40%))
resulting in a relative risk of 0.69 with 95% confidence
interval (0.36, 1.30).
The results of our pilot study are encouraging, but due
to the number of patients enrolled, the effect of iloprost on
early graft function did not reach statistical significance.
There is, however, preliminary evidence to suggest benefi-
cial effects in this particular clinical scenario. The clinical
outcome after LT is affected by various donor and recipient
characteristics such as graft steatosis, long ischemic period
or renal insufficiency prior to LT. In order to define the
specific impact of PGI2 analogue iloprost on liver graft
function, a multicenter, randomized, double-blinded clin-
ical trial including an appropriate number of patients is
justified [20]. This is the objective of our PRAISE study.
Methods/Design
The PRAISE study is a prospective, multi-center, ran-
domized, double blinded (patients and investigators),
placebo-controlled clinical trial according to the German
drug legislation for evaluation of iloprost in the early
postoperative period after LT.
The investigational medicinal product is iloprost
(IlomedinW, Bayer Vital GmbH, Leverkusen, Germany).
The control group receives placebo. Patients will be
assigned to treatment at the ratio of 1:1 according to
a computer generated randomization list by means of
nQuery Advisor software. Randomization will be restric-
ted by blocking with randomly varying block size and
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not involved in the analyses, will prepare the ran-
domization list. The university pharmacy of Heidelberg,
Germany, will provide the trial medication to the partici-
pating centers by sequentially numbered sealed identical
boxes according to the allocation sequence.
The end of trial for each patient is reached 180 days
after LT. The follow-up period will be 6 months with
assessments 9 and 12 months after LT.Study endpoints
The primary endpoint of this trial is the rate of primary
graft dysfunction after liver transplantation. It will be
characterized as presentation of one or more of the fol-
lowing criteria in accordance with Olthoff et al [19]:
ALAT or ASAT level > 2000 IU/ml within the first 7
postoperative days; bilirubin ≥ 10 mg/dl on postoperative
day 7; INR ≥ 1.6 on postoperative day 7 or as occurrence
of initial non-function (INF) defined as graft loss,
retransplantation or patient death within 14 days after
initial LT not secondary to hepatic artery thrombosis
(HAT), biliary complication, recurrent disease or acute
rejection. Based on the results of previous investigations
a relative reduction of PDF incidence of 50% by iloprost
compared to placebo will be expected.
Due to the immunologic capabilities even of the
liver, graft dysfunction may lead to an increased inci-
dence of hospital acquired infections and/or sepsis.
For this reason, the incidence of infectious complica-
tions up to 28 days after LT was defined as an important
secondary endpoint. Further secondary endpoints are the
rate of INF (described above), the graft and patient sur-
vival (28, 180 days after LT), the clotting factor subs-
titution up to day 28 after LT, the rate of biliary
complications, the requirement for liver dialysis, the post-
operative renal replacement therapy (28, 180 days
after LT) and the length of intensive care unit (ICU)
stay and hospital stay. The change in SOFA score
from day 1 to day 7 after LT is used as a surrogate second-
ary endpoint predictive for morbidity and mortality after
LT. The levels of liver enzymes (ASAT/ALAT) may repre-
sent the severity of graft injury due to ischemia/reper-
fusion and the levels of Quick’s value/INR and Factor
V and the ICG-PDR are important parameters of the
synthetic capacity of the graft. Therefore, the course
of these laboratory data until day 7 after LT is also
fixed as secondary endpoint. Occurrence of bleeding
complications, circulatory instability and pulmonary
disturbance during trial intervention as well as inci-
dence of adverse events will be assessed for patient
safety. During the post-trial follow-up graft and pa-
tient survival and biliary complications will be add-
itionally evaluated 9 and 12 months after LT.Further objectives will be explored within the scope of
a scientific supporting program. Liver biopsies, taken
during cold ischemia, after reperfusion and seven days
after LT will be performed for histopathological and
pangenomic gene expression studies. Furthermore, blood
samples will be collected for “multiplex”-analysis of cyto-
kines, chemokines and growth factors in order to in-
vestigate a possible modulating effect of iloprost on the
inflammatory response after LT.
Infection is one of the leading causes of morbidity and
mortality after LT. More than 50% of liver transplant reci-
pients have infections in the first year after transplant-
ation, whereas the majority of bacterial infections occur
within 2 months after transplantation [21]. As the differ-
entiation between infectious and non-infectious etiology
of the so called SIRS (systemic inflammatory response
syndrome) often requires complex and long-lasting tests
valuable time is often lost until the definitive diagnosis of
sepsis can be made. There is a new approach (SIQnatureW,
SIRS-Lab GmbH, Jena, Germany) that allows an analysis
within one working day and facilitates the clinical inter-
pretation according to a score. The data have not yet been
established in patients receiving immunosuppression.
Therefore, within the study setting blood samples will be
taken for the evaluation of the SIQnatureW-test.Study population and setting
Female and male patients aged 18 years and above who are
receiving a full-size liver graft are eligible for the trial.
Complete inclusion and exclusion criteria are displayed in
Table 1. According to the experience from the pilot study
[14] about 83% of primarily enrolled patients reached re-
spiratory and circulatory stable conditions after LT as pre-
condition for trial medication. To randomize 356 patients
after LT written informed consent has to be obtained from
about 430 patients fulfilling the study criteria observable
before LT. In case of patients not able to give informed
consent by themselves informed consent has to be given by
the legal representative. Patients will be recruited in several
German transplant centers. Recruitment was started in
April 2012.Intervention
The investigational medicinal product is iloprost
(IlomedinW, Bayer Vital GmbH, Leverkusen, Germany).
The control group receives placebo administered in the
same dosage and application form. It is the iloprost 10 μg/
ml carrier substance (ethanol, tromethamin, sodium
chloride, hydrochloric acid, water for injections). Patients
will be allocated to the trial medication immediately after
entrance into ICU after LT if respiratory and circulatory
stability is reached (noradrenaline < 1 μg/kgBW/min and
FiO2 < 0,6). The application of the trial medication must
Table 1 Criteria for inclusion and exclusion of patients
Inclusion criteria Exclusion criteria
Full-size liver transplantation
Split liver transplantation or living
donor related liver transplantation
Informed consent of the
patient or legal representative
Participation on other clinical trials 30
days prior to randomization
Age ≥ 18 years
Retransplantation or multivisceral
transplantation
Respiratory and/or circulatory instability
(noradrenaline > 1μg/kgBW/min and
FiO2 > 0,6)
Conditions in which bleeding
complications may be expected from
the effect of Iloprost on platelets
Known allergy or intolerance against
trial medication, tacrolimus,
mycophenolat mofetil, basiliximab or
corticosteroids
Severe coronary artery disease or
unstable angina pectoris
Myocardial infarction within the past 6
months prior to randomization
Acute or chronic heart failure
(NYHA II-IV)
Cardiac arrhythmias relevant for the
prognosis
Suspected pulmonary artery congestion
Women of child-bearing potential
except women with the following
criteria:
○ post menopausal
○ sterilization 86 weeks after bilateral
ovarectomy
○ using an effective method of
contraception during the trial
○ sexual abstinence or vasectomised
partner
Pregnancy/lactation
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reperfusion.
The trial medication will be administered continuously
over a period of seven days intravenously with an infusion
pump. The dosage will be body weight adapted (1 ng/
kgBW/min).
During LT a marked decrease in systemic blood pressure
following liver reperfusion is frequently observed [22]. This
could be aggravated by iloprost due to its vasodilatatory ef-
fect. In our pilot study, clear hemodynamic alterations
under iloprost application were not observed. But we
recorded a higher number of pulmonary complications i.e.
pleural effusion or respiratory impairment. This might be
explained by a PGI2 induced increased intrapulmonary
shunt fraction [23]. Therefore, the trial medication should
be reduced in patients, who present with bleedingcomplications, respiratory disturbances and/or appearance
of hypotension episodes.
The immunosuppressive treatment will be standardized
for both groups to minimize the effects of different im-
munosuppressive treatment within this trial. The trial-
related immunosuppression is based on retard release
Tacrolimus (AdvagrafW) in combination with Basiliximab
(SimulectW) and Mycophenolate Mofetil. Corticosteroids
might be given only as perioperative intravenously bolus.
Study schedule
A schematic view illustrates the Figure 1. All patients or
their legal representatives must give written informed
consent to participate. The screening visit is defined as
assessments made after definition of need for transplant-
ation to confirm eligibility of a particular patient for
entry into this trial. During the screening the following
assessments will be performed: Patient information,
written informed consent, demographic data of the re-
cipient, check for inclusion and exclusion criteria, espe-
cially for existing cardiac and pulmonary diseases.
The baseline visit starts after acceptance of the donor
organ. During the baseline the following assessments
will be made: concomitant medication, non-drug thera-
pies (renal replacement therapy or liver dialysis), the
current baseline data of the recipient (height, weight,
lab-MELD etc.), donor criteria (age, height, weight, BMI,
cause of death, virology data etc. - all data can be
obtained from the Eurotransplant donor protocol) and
the key laboratory data of the recipient.
During the backtable preparation, a wedge biopsy of
the donor liver will be performed. After reperfusion of
the graft (after finishing the bile duct anastomosis), a
further liver biopsy will be done. After entrance to the
ICU, a checking for circulatory and respiratory stability
(noradrenaline < 1 μg/kgBW/min and FiO2 < 0,6) with
assessment of catecholamines, mean arterial pressure,
heart rate, pulmonary disturbances (blood-gas analysis,
FiO2, PEEP, arterial oxygen saturation, pO2, pCO2) is
necessary before randomization of eligible patients.
After that, the trial medication will be started. For
patients not fulfilling the post-LT randomization cri-
teria of circulatory and respiratory stability, the trial is
terminated.
In the treatment period, the patients receive the trial
medication continuously for seven days. During this period,
the following procedures should be performed daily: check
for circulatory and respiratory stability, clotting factor sub-
stitution (FFP, PPSB or other coagulation factor substrates),
infections, appearance of adverse events, concomitant
medication, non-drug therapies, liver dialysis, renal replace-
ment therapy, number of applicated packed red cells, the
blood chemistry and ultrasound of the graft to assess
quality of liver parenchyma and perfusion. In cases of an
Figure 1 Treatment schedule.
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monitored until the tube is clamped for the first time or
at maximum up to day 7 after randomization. An op-
tional measurement of the ICG-PDR with the LiMON-
Technology (PULSION Medical Systems AG, Munich,
Germany) will be performed.
The blood samples for the cytokine analysis are taken
exactly 12 hours after reperfusion, at day 1 and at day
2 after randomization. Further blood samples for the
SIQnatureW – Test are taken on day 1, 3, 7 and 14 after
randomization.
An ultrasound guided percutaneous liver biopsy is per-
formed seven days after LT. In reasonable single cases the
percutaneous liver biopsy may be abandoned if the biopsy
leads to excessive endangerment of the patient or the graft.
Adverse events (AE) occurring after randomization
will be assessed during the trial period up to day 180
after LT. Serious AEs will be managed according to the
requirements of the German drug legislation.
Sample size calculation
The hypotheses to be proved for PDF as primary end-
point at a two-sided 0.05 significance level are:
H0: Incidence (PDF) Iloprost = Incidence (PDF) Placebo
HA: Incidence (PDF) Iloprost ≠ Incidence (PDF) PlaceboThe PDF definition used for this trial was introduced by
Olthoff et al. [19] and validated in a population of 297
liver transplant recipients in the United States who under-
went transplantation in 2004-2005 at three centers. PDF
incidence was 23.2%. We hypothesize that PDF incidence
can be reduced by 50% in patients treated with iloprost
compared to placebo (relative risk RR = 0.5). If, according
to Olthoff, an incidence of 23% will be used as baseline in-
cidence for the placebo group a two-sided Chi2-test will
have 80% power to detect the clinically relevant relative
risk reduction of 50% when the sample size in each group
is 169 (nQuery Advisor 6.01). If the baseline incidence of
PDF will be 40% as observed in the pilot study on the
basis of the Olthoff definition the power will be 98% to
detect the postulated effect of RR = 0.5 for the same sam-
ple size of 169 in each group. Taking into account a post-
randomization dropout rate for primary endpoint data of
5% a total of 356 patients should be randomized.
Statistical analysis
Data will be analyzed for the Clinical Study Report to
EC and the regulatory authority when data from the first
180 days post-LT from all patients are declared complete
and accurate (end of trial). A follow-up analysis will be
performed after all patients complete the follow-up
period of 12 months post-LT.
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analysis data set includes all randomized patients receiving
at least one dose of trial medication. Primary and second-
ary efficacy data will be analyzed by randomized treatment
assignment. The per-protocol (PP) population includes all
randomized patients who are most compliant with the
protocol. Included patients receive at least 80% of planned
trial medication. They complete the study without major
protocol deviations. Major protocol deviations will be
identified and assignment to PP population will be done
at the blind review prior to the 180-day data base lock.
The safety analysis population will include all patients
who receive at least one dose of trial medication. Safety
data will be analyzed by the treatment assignment actu-
ally received.
For primary endpoint, the treatment effect will be esti-
mated as relative risk and odds ratio with 95% confi-
dence interval (CI) and will be tested by Chi2-test.
Analysis of PDF will be possibly adjusted for centre by
logistic regression with random effects. To evaluate the
robustness of results the analysis is repeated for the PP-
population. In explorative analyses the treatment effect
will be further adjusted to known prognostic donor cri-
teria (donor age and BMI, donor serum peak sodium,
cold and warm ischemia time) within a logistic regres-
sion model possibly with random center effects.
The secondary endpoint analyses will be performed in
the ITT population. Incidence of events by treatment
group and relative risks with 95% CI will be estimated
for occurrence of any infection, initial non-function,
clotting factor-substitution, renal replacement therapy
and biliary complications. The Chi2-test will be used for
statistical testing. Length of ICU and hospital stay will
be described by quartiles, means and SD. Hodge-
Lehmann estimates with 95% CI will be calculated as
measure of mean differences, Mann-Whitney U-test is
used for significance testing. Rates of graft or patient
survival will be estimated by the Kaplan-Meier method
at pre-specified time points. Kaplan-Meier curves will be
compared by the log-rank test. The hazard ratio with
95% CI is estimated by the Cox regression model assum-
ing proportional hazards. The course of laboratory data
over time will be analyzed by linear mixed models using
raw or transformed data. Change in SOFA-score will be
analyzed by two-sample t-test. Patients with missing
secondary endpoint data will be excluded from the
respective analysis. There is no interim analysis planned
for efficacy. Annual safety reports will be generated for
the German Competent Authority and the Data
Management and Safety Board.
Ethical and legal aspects
Sponsor of this investigator-initiated trial is the Friedrich
Schiller University Jena. The procedures set out in thetrial protocol are designed to ensure that all persons
involved in the trial abide by ICH-GCP guideline, the
ethical principles described in the applicable version of the
Declaration of Helsinki and the German drug legislation.
The trial was approved by the ethics committee of the
Friedrich Schiller University Jena, Faculty of Medicine and
the German Competent Authority (BfArM) (EudraCT-
Number: 2010-022660-12). The study is registered at the
German Clinical Trials Register (DRKS00003514) and in
the Current Controlled Trial Register (ISRCTN12622749).Responsibilities
Coordinating investigator: Prof. Dr. Utz Settmacher,
Head of the Department of General, Visceral and Vascu-
lar Surgery, Jena University Hospital, Germany.
Trial statistician: Dr. Heike Hoyer, Institute of Medical
Statistics, Information Sciences and Documentation,
Jena University Hospital, Germany.
Project Management: Department of General, Visceral
and Vascular Surgery, Center for Clinical Studies, Jena
University Hospital, Germany.
Clinical monitoring, safety and data management:
Coordination Centre for Clinical Trials (KKS), University
Halle, Germany.Discussion
Due to the shortage of donor organs, transplant centers
are forced to accept so-called marginal organs. Thus,
there is a significant interest in the development of new
strategies to prevent graft dysfunction and early graft
loss. Apart from technical complications (vascular and
biliary), acute or chronic rejection, PDF accounts for the
majority of indications for re-transplantation [24]. The
cause of graft dysfunction is multi-factorial, but IRI plays
an important role as being characterized by a severe
impairment of organ microcirculation [25]. In several ex-
perimental models, prostaglandins (PG) protected the liver
from severe damage induced by ischemia and reperfusion
[26-29]. Several authors reported a significant decrease of
liver enzyme levels after application of PG and a favorable
clinical course [30,31]. Nevertheless, its prophylactic ad-
ministration after LT is still a subject of discussion, because
the investigators did not identify a beneficial effect on graft
function itself [32,33].
The aim of our study is the investigation of the impact of
continuous intravenous administration of PGI2 analogue
iloprost after LT in order to prevent graft dysfunction.
In order to define the specific impact of PGI2 analogue
iloprost on liver graft function, this multi-center study in-
cluding a larger number of patients and will enable reliable
risk stratification according to the MELD score or
extended donor criteria. This upcoming trial will be under
the patronage of the German Transplantation Society.
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